Monographie - Daunorubicin hydrochloride

Τελευταία ενημέρωση :
19/11/2024

Daunorubicin hydrochloride

χημική δομή

Εμπορική ονομασία

Οι εμπορικές ονομασίες είναι ενδεικτικές και η σύνθεση των εκδόχων μπορεί να διαφέρει ανάλογα με τη χώρα και τα εργαστήρια

Cerubidin	Δανία, Ιρλανδία, Μεγάλη Βρετανία, Νορβηγία, Σουηδία
Cerubidine	Βέλγιο, Γαλλία, Ελβετία, Η.Π.Α., Καναδάς, Λουξεμβούργο, Μαρόκο, Ολλανδία, Τουρκία, Τυνησία, Χιλή
D Blastin	Μαρόκο
Daunac	Κολομβία
Daunobin	Ινδία
Daunoblastin	Αυστρία, Γερμανία
Daunoblastina	Βενεζουέλα, Ελλάδα, Ιράν, Ισπανία, Ιταλία, Ουγγαρία, Σαουδική Αραβία
Daunocin	Ινδία, Μαλαισία, Περού
Daunogobbi	Αργεντινή
Daunomed	Ινδία, Περού
Daunomycin	Ινδία
Daunoplus	Ινδία
Daunorubicin	Αυστραλία, Η.Π.Α., Καναδάς, Μεγάλη Βρετανία, νέα Ζηλανδία
Daunorubicina	Εκουαδόρ, Κολομβία, Μεξικό, Περού, Χιλή
Daunorubitec	Ινδία
Daunoside	Ινδία
Daunotec	Βενεζουέλα, Ινδία
Daurocina	Χιλή
Epodoxo	Περού
Maxidauno	Αργεντινή, Εκουαδόρ
Oncodaunotec	Κολομβία
Rubilem	Μεξικό
Runabicon	Κολομβία, Μεξικό
Zuleb	Μεξικό

Βιβλιογραφία : Daunorubicin hydrochloride

	τύπος	δημοσίευση
3	εφημερίδα	Trissel LA, Martinez JF. Compatibility of amifostine with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
81	εφημερίδα	Trissel LA, Martinez JF. Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 672-678.
84	εφημερίδα	Trissel LA, Martinez JF. Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1994 ; 51: 495-499.
99	εφημερίδα	Trissel LA, Martinez JF. Compatibility of aztreonam with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
148	εφημερίδα	Dine T, Cazin JC, Gressier B, Luycks M, Brunet C, Cazin M, Goudaliez F, Mallevais ML, Toraub I. Stability and compatibility of four anthracyclines: doxorubicin, epirubicin, daunorubicin and pirarubicin with PVC infusion bags. Pharm Weekbl [Sci] 1992 ; 14: 365-369.
150	εφημερίδα	Aujoulat P, Coze C, Braguer D, Raybaud C. Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens. J Pharm Clin 1993 ; 12: 31-35.
152	εφημερίδα	Chevrier R, Sautou V, Pinon V, Demecop F, Chopineau J. Stability and compatibility of a mixture of the anti-cancer drugs etoposide, cytarabine and daunorubicine for infusion. Pharm Acta Helv 1995 ; 70: 141-148.
169	εφημερίδα	Trissel LA, Martinez JF. Physical compatibility of melphalan with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1993 ; 50: 2359-2363.
244	εφημερίδα	Trissel LA, Martinez JF. Compatibility of filgrastim with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1907-1913.
249	εφημερίδα	Trissel LA, Martinez JF. Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration. Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
307	εφημερίδα	Trissel LA, Martinez JF. Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration. Am J Hosp Pharm 1994 ; 51: 1792-1799.
334	εφημερίδα	Trissel LA, Tramonte SM, Grilley BJ. Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 988-992.
492	εφημερίδα	Trissel LA, Parks NPT, Santiago NM. Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection. Am J Hosp Pharm 1991 ; 48: 2186-2189.
632	εφημερίδα	Beijnen JH, Rosing H, De Vries PA, Underberg WJM. Stability of anthracycline antitumour agents in infusion fluids. J Parenter Sci Technol 1985 ; 39: 220-222.
643	εφημερίδα	Seargeant LE, Kobrinsky NL, Sus CJ, Nazeravich DR. In vitro stability and compatibility of daunorubicin, cytarabine, and etoposide. Cancer Treat Rep 1987 ; 71: 1189-1192.
686	εφημερίδα	Wood MJ, Irwin WJ, Scott DK. Stability of doxorubicin, daunorubicin and epirubicin in plastic syringes and minibags. J Clin Pharm Ther 1990 ; 15: 279-289.
905	εφημερίδα	Trissel LA, Martinez JF. Screening teniposide for Y-site physical incompatibilities. Hosp Pharm 1994 ; 29: 1010-1017.
1265	εφημερίδα	Wood MJ, Irwin WJ, Scott DK. Photodegradation of doxorubicin, daunorubicin and epirubicin measured by high-performance liquid chromatography. J Clin Pharm Ther 1990 ; 15: 291-300.
1284	εφημερίδα	Williams BA, Tritton TR. Photoinactivation of anthracyclines. Photochem Photobiol 1981 ; 34: 131-134.
1410	εφημερίδα	Trissel LA, Martinez JF, Simmons M. Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 141-145.
1423	εφημερίδα	Trissel LA, Martinez JF, Gilbert DL. Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection. J Am Pharm Assoc 1999 ; 39: 514-518.
1520	Εργαστήριο	Etude de stabilité des médicaments en Ecoflac® B Braun 2001
1625	εφημερίδα	Trissel LA, Saenz C, Williams YW, Ingram D. Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2001 ; 5: 314-321.
1897	εφημερίδα	Sautou-Miranda V, Brigas F, Thibault M, Chopineau J. Compatibility of doxorubicin, daunorubicin and epirubicin with low-density polyethylene and polyvinyl chloride, and stability in various conditions of storage. EJHP 2001 ; 7, 3: 108-115.
1982	εφημερίδα	Trissel LA, Ogundele AB. Compatibility of anidulafungin with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2005 ; 62: 834-837.
2247	εφημερίδα	Chan P, Heatherly K, Kupiec T.C, Trissel L.A. Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration. Int J Pharm Compound 2008 ; 12, 3: 276-278.
3438	εφημερίδα	Respaud R, Quenum L, Plichon C, Tournamille J.F, Gyan E, Antier D, Viaud-Massuard M.C. A stability-indicating, ion-pairing, reversed-phase liquid chromatography method for studies of daunorubicin degradation in i.v. infusion fluids. J Pharm Biomed Anal 2013 ; 83 : 164-170.
3474	Εργαστήριο	Fluorouracil - Summary of Product Characteristics Accord Healthcare Limited 2009
3540	Εργαστήριο	Heparin sodium - Summary of Product Characteristics. Wockhardt 2010
3604	Εργαστήριο	Daunorubicine (Cérubidine®) - Résumé des caractéristiques du produit Sanofi Aventis France 2012
3668	Εργαστήριο	Dexamethasone - Summary of Product Characteristics Hospira 2015

Mentions Légales